SUNPHARMA
Natco Pharma for 45%+ gainsDate: 21 Nov’24
Symbol: NATCOPHARM
Timeframe: Daily
Natco Pharma currently seems to be in Wave IV of 3 which could end around 1240-1220 and Wave V could then head towards 1800-1900 levels (45%+ from where Wave IV would end) as seen in the chart. A more precise target can be pinned once it makes a fresh ATH. Two levels (1770 & 1900) have been marked as possible supply zone.
The company recently posted good Q2 numbers. The stock is currently trading at a PE multiple of 12.6 while the industry average is around 32.
This is not a prediction but a possible wave count. This is also not a recommendation to trade or invest. Please do your own analysis.
HINGLISH VERSION
Natco Pharma vartamaan mein 3 ke Wave IV mein hai, jo 1240-1220 ke aaspaas samaapt ho sakta hai aur Wave V phir 1800-1900 ke star (45%+ jahaan Wave IV samaapt hoga) kee taraf badh sakta hai, jaisa ki chart mein dekh sakte hain. Ek baar naya ATH banaane par adhik sateek target pin kiya ja sakta hai. Do staron (1770 aur 1900) ko sambhaavit supply zone ke roop mein mark kiya gaya hai.
Company ne haal hee mein achhe Q2 ke numbers post kiye hain. Stock vartamaan mein 12.6 ke PE multiple par kaarobaar kar raha hai jabki industry ka average lagbhag 32 hai.
Yah koee bhavishyavaanee nahin balki sambhaavit Wave count hai. Yah trade lene ya invest karne ki bhi salaah nahi hai. Kripya apana vishleshan svayan karen.
Granules India for 35%+ gainsDate: 3 Oct’24
Stock: Granules
Timeframe: Daily chart
Granules India seems to have begun its up move in Wave V of 5 which could end around 810-820 (>35% from current price of 595) as seen in the chart. High volumes and strong reversal of RSI supports this stance.
This is not a trade recommendation. Please do your own analysis.
Aisa lagata hai ki Granules India ne 5 ke Wave V mein apni badhat shuroo kar dee hai, jo 810-820 (595 kee vartamaan keemat se 35%) ke aasapaas samaapt ho sakatee hai, jaisa ki chart mein dekh sakte hain. Achhi volume aur RSI ka majaboot ulataav is rukh ka samarthan karta hai.
Yeh koi vyaapaar ki rai nahin hai. Kripya apna vishleshan khud karein.
Sun Pharmaceutical, Bearish - SidewaysThe stock has seen exponential rise since last many months without any intermittent major corrections. The fresh trend lines created have been breached now, and stock seems to have entered into sloping / sideways channel since Feb. Expect to see corrections upto 1300-1250 or upto the trend line which will be healthy for accumulation & gather momentum for future uptrend.
SPARC Breaking Channel Formation Above 250Details:
Asset: Sun Pharma Advanced Research Company Ltd (SPARC)
Breakout Level: Above 250
Potential Target: Upside momentum expected
Stop Loss: Below breakout level or as per risk tolerance
Timeframe: Short to medium-term
Rationale: Sun Pharma Advanced Research Company Ltd (SPARC) is showing signs of a potential breakout above the 250 level, breaking out of a channel formation. Sustaining above this level could indicate a bullish sentiment shift and pave the way for a significant upmove.
Market Analysis:
Technical Breakout: Breaking out of the channel formation and sustaining above 250 suggests a technical breakout, potentially attracting buying interest and driving the price higher.
Market Sentiment: Positive market sentiment or company-specific factors may be contributing to the anticipated breakout in SPARC.
Potential Target:
The potential upside target for SPARC is not specified but is expected to be significant if the breakout sustains.
Risk Management:
Implementing a stop loss strategy below the breakout level is essential to manage risk in case of unexpected price reversals.
Timeframe:
The projected upside move for SPARC is based on a short to medium-term outlook, but actual timing may vary based on market conditions.
Risk-Reward Ratio: Consider individual risk tolerance and adjust position size accordingly to maintain a favorable risk-reward ratio.
As with any investment opportunity, conduct thorough analysis and consider factors such as market trends, company fundamentals, and risk management strategies before making trading decisions.
Sun Pharma, Stocks to keep in focus for coming sessions Intraday Stocks to Focus for coming sessions
Sun Pharma is showing consolidation from past few sessions
Momentum can come if decisively sustains outside the Range 1640 to 1580
Keep Tracking Charts
* For Educational purposes
Learn and Practice Price Action Setups
Double Moving Averages Crossover Swing Trade📊 Script: JINDALSTEL
📊 Nifty50 Stock: NO
📊 Sector: Steel
📊 Industry: Steel - Sponge Iron
⏱️ C.M.P 📑💰- 849
🟢 Target 🎯🏆 - 890
⚠️ Stoploss ☠️🚫 - 825
📊 Script: VTL
📊 Nifty50 Stock: NO
📊 Sector: Textiles
📊 Industry: Textiles - Cotton/Blended
⏱️ C.M.P 📑💰- 442
🟢 Target 🎯🏆 - 472
⚠️ Stoploss ☠️🚫 - 425
📊 Script: JSWENERGY
📊 Nifty50 Stock: NO
📊 Sector: Power Generation & Distribution
📊 Industry: Power Generation And Supply
⏱️ C.M.P 📑💰- 528
🟢 Target 🎯🏆 - 561
⚠️ Stoploss ☠️🚫 - 511
📊 Script: NYKAA
📊 Nifty50 Stock: NO
📊 Sector: E-Commerce/App based Aggregator
📊 Industry: Trading
⏱️ C.M.P 📑💰- 161
🟢 Target 🎯🏆 - 173
⚠️ Stoploss ☠️🚫 - 155
📊 Script: SUNPHARMA
📊 Nifty50 Stock: YES
📊 Sector: Pharmaceuticals
📊 Industry: Pharmaceuticals - Indian - Bulk Drugs
⏱️ C.M.P 📑💰- 1620
🟢 Target 🎯🏆 - 1692
⚠️ Stoploss ☠️🚫 - 1590
⚠️ Important: Always maintain your Risk & Reward Ratio.
✅Like and follow to never miss a new idea!✅
Disclaimer: I am not SEBI Registered Advisor. My posts are purely for training and educational purposes.
Eat🍜 Sleep😴 TradingView📈 Repeat 🔁
Happy learning with trading. Cheers!🥂
SUNPHARMA Prediction for Swing Trading SUNPHARMA Prediction for Swing/ Posional Trading
Breakout at entry (1162) level. Entry can be retest in future.
Sls- according to you RRR.
Targets- 1180,1200,1215,1235,1255,1275,1275,1315,1350,… (more will be updated later if need )
According to your “STOMACH” book your profit. Always maintain your risk management.
Watch Carefully – The Chart Explains For Itself.
Disclaimer:
I am not a SEBI Registered Analyst. Anything posted here is my own analysis and views. This is created for educational purposes only. Always consult your Financial Advisor before taking any decision or trade.
Happy trading.
About SUNPHARMA –
Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.
How to identify a multibagger stock?Ways to identifty a multibagger and a good stock for positional trade:
The stock should fulfill the following criteria
1.It should be from a booming sector and the broader index should be uptrending
2.The relative strength of the stock to Nifty 50 should be in uptrend
3.RSI should be above 40
4.The stock should be in a stage 2 uptrend structure (breakout with good volumes + consolidation --> breakout with good volumes as shown in the structure of sun pharma)
5.The stock should have low volume consolidation.
Many more examples are there from the realty sector and few from the financial sector and I will be uploading them very soon FOLLOW me to get notified when i upload a new idea
Till then,
Happy Trading :)
SUNPHARMA - Ichimoku Breakout📈 Stock Name - Sun Pharmaceuticals Industries Limited
🌐 Ichimoku Cloud Setup:
1️⃣ Today's close is above the Conversion Line.
2️⃣ Future Kumo is Turning Bullish.
3️⃣ Chikou span is slanting upwards.
All these parameters are shouting BULLISH at the Current Market Price and even more bullishness anticipated AFTER crossing 1380.
🚨 Disclaimer: This is not a Buy or Sell recommendation. It's for educational purposes and a guiding light to learn trading in the market.
#CloudTrading
#IchimokuCloud
#IchimokuFollowers
#Ichimokuexpert
Excited about this analysis? Share your thoughts in the comments below!
👍 Like, Share, and Subscribe for daily market insights! 🚀
#StockAnalysis #MarketWatch #TradingEducation #ichimoku
Positional_ SunpharmaSunpharma looks good for a positional/swing trade.
Buying above Rs 690, SL Rs 677.90, Target to be updated soon.
Disclaimer: The views expressed in this article is of my own. You're solely responsible for any decision taken in the markets, resulting in financial gains or losses. The analysis I've shared is for informational and educational purposes only.